



Molecular Pharming for Cancer Vaccines and Treatment

Guest Editors:

Dr. Srividhya Venkataraman

Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Deadline for manuscript submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear colleagues,

This special issue of 'Vaccines' invites original research articles and reviews concerning the current state of the art of plant-derived technologies to preclude or treat cancers. This issue addresses plant-based production systems that preclude solid tumors, lymphomas and infection by oncogenic viruses along with plant-based cancer immunotherapy (monoclonal antibodies) for use in developing countries. Also addressed by this current issue are plant-derived pharmaceuticals that have been developed to fight cancer. The recent discovery of plant virus nanoparticles (VNPs) that target and penetrate solid tumors is particularly exciting. Plant viral nanoparticles can be produced in a facile manner with drugs functionalized to their surfaces, enabling them to easily home in and block tumor progression.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)